Efficacy Of Paclitaxel And Albumin-bound Paclitaxel In Neoadjuvant Chemotherapy For Human Epidermal Growth Factor Receptor-2(HER2)Negative Breast Cancer

Objective:We compare the clinical efficacy and safety of epirubicin with sequential paclitaxel or albumin-bound paclitaxel in neoadjuvant chemotherapy of HER-2-negative breast cancer,and provide guidance for clinical drug selection.Methods:80 newly diagnosed invasive breast cancer patients from December 2015 to August 2017 in our hospital was retrospectively analyzed.39 patients were treated with paclitaxel,named group A;41 patients were treated with albumin-bound paclitaxel,named group B.By analyzing the breast mammography resonance(MR)reports scanning before the neoadjuvant chemotherapy,before the fifth cycle,before the operation and postoperative pathology report to evaluate chemotherapy efficacy and adverse reactions.Results:The Overall Response Rate(ORR)of group A and group B were 75.00%and 78.04%respectively,P=0.798.The pathological completely response rate of the two groups were 7.50%and 24.39%,P=0.067,respectively,without statistically significant difference.Subgroup analysis showed that the pathological completely response(pCR)of A groups of hormone receptors positive rate was 7.40%which was slightly less than group B,P=0.671,and the pCR rate of triple negative breast cancer(TNBC)in group A was 7.69%,which was significantly lower than that in group B(50.00%,P=0.030);The incidence rate of adverse reactions in groups A and B were 53.78%? 54.62%,respectively,P=0.825.Conclusions:Neoadjuvant chemotherapy with paclitaxel or albumin-bound paclitaxel in patients with HER-2 negative breast cancer can receive similar overall response rate and safety.For HR-positive patients,the pCR rate of paclitaxel and albumin binding paclitaxel was similar,and there was no statistical difference but in TNBC patients the albumin-bound paclitaxel is easier to obtain higher pCR rate.